Meeting
2021 ASCO Annual Meeting
Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: A clinical trial update.
Authors
Eric Jeffrey Sherman
Memorial Sloan Kettering Cancer Center, New York, NY
Eric Jeffrey Sherman , Lori J. Wirth , Manisha H. Shah , Maria E. Cabanillas , Bruce Robinson , Janessa J. Laskin , Matthias Kroiss , Vivek Subbiah , Alexander E. Drilon , Jennifer Wright , Victoria Soldatenkova , Pearl Plernjit French , Antoine Italiano , Daniela Weiler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
NCT03157128
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6073)
DOI
10.1200/JCO.2021.39.15_suppl.6073
Abstract #
6073
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer.
First Author: Manisha H. Shah
Poster
2021 ASCO Annual Meeting
Efficacy of selpercatinib after prior systemic therapy in patients with RET mutant medullary thyroid cancer.
First Author: Lori J. Wirth
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Durable efficacy of selpercatinib in patients with RET fusion+ solid tumors, with a focus on GI tumors: LIBRETTO-001.
First Author: Vivek Subbiah
Poster
2022 ASCO Annual Meeting
Tumor agnostic efficacy of selpercatinib in patients with RET fusion+ solid tumors: A global, multicenter, registrational trial update (LIBRETTO-001).
First Author: Vivek Subbiah